达美康联合胰岛素降糖在糖尿病肾病腹膜透析患者中的应用价值及安全性分析

目的：研究达美康联合胰岛素降糖在糖尿病肾病腹膜透析患者中的应用价值和安全性。方法：将在我院接受腹膜透析治疗的66例终末期糖尿病肾病患者纳入研究，随机分为给予终末期糖尿病肾病治疗的观察组和仅给予胰岛素降糖治疗的对照组。治疗后6周时，比较两组血糖水平、胰岛素用量、肾功能情况以及不良反应例数。结果：治疗后6周时，观察组空腹血糖、餐后血糖、糖化血红蛋白含量、单日胰岛素用量以及血肌酐、血尿素氮、三酰甘油水平均低于对照组，血糖控制达标率高于对照组，差异有统计学意义（P〈0．05）；治疗6周内，观察组发生腹膜炎、心血管事件、低血糖反应、死亡的例数少于对照组，差异有统计学意义（P〈0．05）。结论：达美康联合胰岛素降糖治疗有助于控制血糖水平、降低胰岛素用量、改善肾功能、减少不良反应发生率，是终末期糖尿病肾病腹膜透析患者理想的降糖方案。

Analysis of the application value and safety of Diamicron combined with insulin hypoglycemic therapy in diabetic nephropathy patients received peritoneal dialysis

Objective： To study the application value and safety of Diamicron combining with insulin hypoglycemic therapy in diabetic nephropathy patients received peritoneal dialysis. Methods： 66 endstage diabetic nephropathy patients receiving peritoneal dialysis were enrolled and randomly divided into observation group and control group, which were given Diamicron combining with insulin and simple insulin, respectively. After 6 weeks of treatment, blood glucose levels, insulin consumed dosage, renal function and number of cases of adverse reactions were observed. Results. After 6 weeks treatment, fasting blood glucose level, postprandial blood glucose level, glycated hemoglobin content, daily insulin dosage and serum creatinine levels, blood urea nitrogen triacylglycerol levels of observation group were lower than those of control group, blood glucose control compliance rate of the observation group was higher than control group. During the 6 weeks of treatment, number of cases of peritonitis, hypoglycemia, cardiovascular events, death of observation group were less than those of control group （P〈0.05）. Conclusion. Diamicron combining with insulin are ideal hypoglycemic therapy in end-stage diabetic nephropathy patients receiving peritoneal dialysis, and it is helpful to control blood glucose levels, reduce the dosage of insulin, improve kidney function, reduce the incidence of adverse reactions.